Opinion|Videos|January 20, 2025
Emerging Therapies: a look at the current data: PROTECT study
Key Takeaways
- Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
- Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
Panelists discuss how the PROTECT study’s results enhance the understanding of emerging therapies for IgA nephropathy, focusing on their potential to reduce proteinuria and modify disease progression.
Advertisement
Episodes in this series
- In the phase 3 ALIGN trial (
NCT04573478 ), atrasentan demonstrated a 36% relative reduction in proteinuria with placebo after 36 weeks of treatment. What other data points would be relevant for clinicians?
Advertisement
Related to this article
Robert Mentz, MD, discusses mentorship, trial recruitment, journal growth, and surgical partnerships in heart failure care.
Advertisement
Advertisement
Trending on HCPLive
1
Single Dose of CIDEB siRNA Normalizes Liver Fat in MASLD Through 36 Weeks
2
Lp(a)HORIZON, Oral PCSK9s, and 2027 Lipid Trials, with Kausik Ray, MD, MBChB, MPhil
3
COMP360 Psilocybin NDA Submitted to FDA for Treatment-Resistant Depression
4
What’s New in the 2027 GOLD Report for COPD
5